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Abstract 
Background: In the last few decades, Computed Tomography Enterography 
(CTE) and Magnetic Resonance Enterography (MRE) have become crucial weapons for 
the evaluation of patients with Crohn’s Disease (CD). Despite the many studies on the 
role of cross sectional imaging in the diagnosis and assessment of CD activity, there are 
few related to their impact on the patients’ outcome. 
Methods: The study group for this retrospective study was composed of 349 
patients previously diagnosed with CD, who underwent CTE/MRE from January 2010 
to December 2015. Epidemiological and clinical data were collected from patients’ 
clinical reports as well as CTE and MRE findings and their influence on management 
plan. Chi-square test and Fisher’s exact test were used to evaluate the statistical 
significance. 
Results: 349 cases were evaluated, of which 85% underwent CTE and 15% 
MRE. Overall, 60 patients had no CTE/MRE evidence of active disease and 289 had 
abnormal exams, of which the most frequent findings included bowel wall thickening 
and mural hyperenhancement. The CTE and MRE studies influenced a change in 
management in 40% of patients, leading more frequently to the introduction of 
immunomodulators (10%), anti-TNFα agents (8%) and corticosteroids (6%). Mural 
stratification was the only sign shown to be strongly related to change in management. 
Conclusions: CTE and MRE played a decisive role in the outcome, leading to a 
therapeutic change in 40% of patients, and mural stratification, a sign of gravity, was 
strongly related with the outcome, leading to change in management in 46% of patients. 
Our findings further support the use of this imaging techniques in CD management 
algorithms. 
Key Words: “Crohn’s Disease”, “Magnetic Resonance”, “Computed 
Tomographic”, “Enterography” and “Management Plan”. 
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Introduction 
Crohn’s Disease (CD) is a chronic inflammatory bowel disease with a peak 
incidence between the second and fourth decades of life, characterized by an 
unpredictable course, marked by relapses and remissions.
1
 It can affect any part of the 
gastrointestinal tract, from the mouth to the anus, with about 80% of cases involving the 
small bowel, particularly the terminal ileum.
2
 The inflammation manifests itself by 
ulceration, which can range from superficial lesions to deep ulcers, with areas of 
inflammation interspersed with regions of normal mucosa (skip lesions). The transmural 
nature of CD always leads to stricturing or penetrating disease with intestinal 
obstruction and formation of fistuleas and abscesses.
3
 The annual incidence of Crohn's 
Disease is estimated at 12.7 per 100,000 people in Europe and 20.2 per 100,000 people 
in North America. Its increasing incidence in both developed and developing countries 
shows the emergency of CD as a global disease.
4
 
Several clinical indices have been developed in order to assess and quantify the 
severity of the disease. The most commonly used are the CD Activity Index and the 
Harvey Bradshaw Index, which classify the disease from asymptomatic remission to 
severe disease.
5
 With the recent introduction of effective medication, such as anti-TNF 
agents, “mucosal healing” is considered as the target of therapy for CD. This requires 
full disease assessment based not only on clinical and endoscopic data, but also on the 
findings of imaging techniques.
6
 
Ileocolonoscopy is the gold standard for direct visualization of the colon’s 
mucosa and for obtaining material for histological study through biopsies and it remains 
the ideal method for objective evaluation of disease activity in CD.
7,8
 However, in 
addition to not being able to evaluate the trans-mural extent of the disease, another 
major limitation of endoscopy is the inability to classify the disease severity at the level 
of the small intestine or to evaluate extra-luminal complications.
5
 Thus, cross-sectional 
imaging is becoming indispensable in the evaluation and classification of the severity of 
CD, since it allows the imaging of the entire gastrointestinal tract, observation of the 
bowel wall and evaluation of extra-intestinal complications, providing additional 
information and enabling clinicians to make more informed decisions regarding to 
patients’ management plans.9 In the last consensus of the European Crohn’s and Colitis 
Organisation, Computed Tomography Enterography (CTE) and Magnetic Resonance 
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Enterography (MRE) are the imaging techniques recommended to determine the extent 
of CD in the small intestine.
10
  
CTE is widely used in the diagnosis of CD and evaluation of disease activity. 
Nevertheless, this imaging technique resorts to ionizing radiation with an adverse 
cumulative effect for patients, which is of extreme importance in CD since it affects 
mainly young adults and has a course marked by frequent relapses. Therefore, a free-
radiation alternative is preferred, as is the case of MRE.
7
 There have been several 
studies comparing the effectiveness of MRE and CTE for detecting active inflammatory 
disease. A recent meta-analysis including 290 patients from 6 different studies 
diagnosed with CD showed that CTE and MRE have comparable sensitivity and 
specificity for demonstrating disease activity and detecting CD’s complications.11  
An accurate assessment of disease characteristics is essential for proper 
management of CD, with prognostic implications.
12
 Treat-to-target strategies are viewed 
as essential to the goal of altering the natural history of CD.
13
 With the increased use of 
cross sectional imaging in diagnosis and monitoring of CD, MRE-based severity scores 
have been developed and discussed. These severity scores can provide a better 
description of inflammatory lesions and severity assessment and may be useful in 
clinical practice to guide treatment decisions and in the evaluation of therapeutic 
efficacy.
 13
 Rimola et al
14
 proposed and validated the most widely used severity score - 
“Magnetic Resonance Index of Activity” (MaRIA). This score takes into account bowel 
wall thickness, mucosal hyperenhancement and presence of edema and ulcers.
 5
 MaRIA 
score was shown to be highly correlated with the CD Endoscopic Index of Severity 
(CDEIS), the reference gold standard for endoscopic evidence of disease.
 13
  
Despite the many studies on the role of CTE and MRE in the diagnosis and 
detection of CD activity, there are few related to their impact on the outcome of these 
patients.
 3
 The objectives of the present study were to evaluate how CTE and MRE 
influence the clinician’s therapeutic decision in patients with CD and to assess the 
impact of specific radiological signs in this decision. 
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Materials and Methods 
This paper is based on a retrospective study of 349 patients of Centro Hospitalar 
de São João (CHSJ), with an established diagnosis of CD and who underwent CTE or 
MRE from January 2010 to December 2015. Patients with “suspected CD” as an 
indication were not included in this analysis. Patients with a diagnosis of Indeterminate 
Colitis or Ulcerative Colitis were excluded from our study. The cases in which more 
than 4 months had elapsed between the CTE or MRE evaluation and the change in 
management plans were also excluded. 
The list of patients who underwent CTE or MRE between January 2010 and 
December 2015 was provided by the Radiology Department of CHSJ’s. The clinical 
variables analyzed in our study were collected from the database of the Grupo de 
Estudos de Doença Inflamatória Intestinal (GEDII). 
Of the 923 patients with inflammatory bowel disease who underwent CTE and 
ERM between 2010 and 2015 at our institution, 454 were excluded due to insufficient 
data for the analyses; 28 were excluded due to their diagnosis of Ulcerative Colitis or 
Undetermined Colitis; 19 were excluded because there was more than 4 months 
between the CTE or MRE assessment and the change in management, and 73 were 
excluded because these exams were performed with the purpose of aiding the diagnosis 
of CD.  
Data Collection  
Clinical and Demographic Data 
Clinical data related to the Montreal Classification, which includes age at the 
diagnosis (A1 - ≤16 years old; A2 - 17-39 years old; and A3 - ≥40 years old); disease 
behavior (B1 – non stricturing non penetrating; B2 – stricturing; e B3 – penetrating; and 
p - perianal disease) and disease location (L1 - ileal; L2 - colonic; L3 - ileocolonic; and 
L4 – upper gastrointestinal tract), were collected. Clinically, this classification of CD 
has benefits in terms of patient counseling, assessment of disease prognosis, and 
providing support for the clinicians' decision of the most appropriate therapeutic plan 
for each disease subtype.
 15,16
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Other data obtained included clinical data related to a family history of CD, 
clinical occurrences during the course of the disease ("Emergency Service", 
"Hospitalizations" and "Surgeries"), reasons and clinical circumstances of CTE or MRE 
evaluation ("Acute disease" or "Follow-up"; “Hospitalization” or "Ambulatory") and 
previous upper and/or low digestive endoscopy. 
The baseline characteristics of the patients are represented in table 1. 
 
Prior Endoscopic Study 
In an attempt to avoid possible detection biases, previous endoscopic studies 
were evaluated, estimating their possible influence on patient outcome. We took into 
account the studies that were included in the consultation report, in which CTE or MRE 
were evaluated. 
 
CTE and MRE Reports 
Any signs pertaining to disease activity were collected based on the original 
CTE and MRE reports (multiple radiologists) by one of the authors, and And the doubts 
were discussed with the other authors. The CTE and MRE findings recorded included: 
“Bowel wall thickening”, “Mucosal enhancement”, “Mural stratification”, “Comb sign”, 
“Ulcer”, “Fistulae”, “Abscess” and “Stenosis” (table 2).  
 
Follow-up and Patient Management 
Pre- and post-CTE/MRE’s therapeutic plans collected from the clinical file of 
the patient, were analyzed for outcome evaluation. The drugs were grouped into eight 
categories: “Immunomodulators” (Azathioprine and Methotrexate), “Anti-TNFα 
agents” (Infliximab, Adalimumab and Golimumab); “Corticosteroids”; 
“Aminosalicylates”; “Polymeric diet”; and “Surgery”. Subsequently, possible outcomes 
were categorized as: "No change in management", "Escalating therapy" and "De-
escalating therapy"; which were subcategorized as shown in table 3. 
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Statistical Analysis  
Descriptive analysis included demographic and clinical data were reported as a 
number (percent) or median (minimum, maximum, percentiles) as appropriate. The Chi-
square test and Fisher’s exact test were used to calculate significant associations 
between the age of diagnosis, disease location and disease behavior and management; 
the cause and the context of CTE and MRE and management; endoscopy and 
management; CTE/MRE findings and management; and CTE/MRE findings and 
specific outcomes. P values less than 0.05 were considered significant.  
Data were analyzed by using standard statistical software, SPSS (IBM Corp. 
Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM 
Corp.). 
Ethical Considerations 
This study was approved by the The Ethical Commission for Health and 
authorized by the board of directors of Centro Hospitalar de São João. 
 
Results 
A total of 349 patients were included in the study [161 were females, 188 males, 
with a median age of 34 years old (ranging from 11 to 76; 25
 
percent were 24 and 75 
percent were 47) and a median age at the time of diagnosis of 24 (25 percent were 24 
and 75 percent were
 
47)] of which 85% underwent CTE and the remaining 15% MRE. 
Overall, 78% of CTE or MRE were performed with the objective of monitoring the 
disease activity, and the remaining 22% due to the manifestation of acute disease. In 
83% of cases, CTE or MRE were performed as part of a consultation, while 17% were 
performed during hospitalization. 
The majority of cases in the study (64%) received a diagnosis between the ages 
of 17 and 40, presenting a non-stricturing and non-penetrating behavior (30%) and a 
predominantly ileal (45%) and ileocolonic (44%) disease. Baseline characteristics of the 
patients included in our study are presented in table 1. 
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Prior Endoscopic Study 
Of the 349 patients in the study, 122 (36%) had undergone at least one type of 
endoscopic exam. Of these 122 patients, 2 were subjected only to upper digestive 
endoscopy, 93 to lower digestive endoscopy, and 27 to both. 
 
CTE and MRE Reports 
Radiologists reported 57 different combinations of radiological signs with an 
average of 2.25 findings per CTE or MRE, ranging from 0 to 6 findings. The two most 
common findings included bowel wall thickening and mucosal enhancement (table 2).  
Of the 349 CTE or MRE performed, 60 were considered normal, of which 70% 
maintained the treatment plan while 30% changed it. Of the 289 abnormal exams, 42% 
changed the management plan while 58% maintained the treatment plan. No statistically 
significant association was found between a normal or abnormal exam and outcome (p 
= 0.087). 
 
Patient Management 
After CTE or MRE, 139 patients (40%) changed the management plan, and 
some therapeutic decisions were included in more than one category. The three most 
frequent alterations included the introduction of an immunomodulator agent (10%), the 
introduction of an anti-TNFα agent (8%) and the introduction of a corticosteroid (6%). 
The results related to patients’ outcome are expressed in table 4. 
 
Association between clinical factors and endoscopic study with change in 
management 
Age at the diagnosis, disease behavior and disease location were not statistically 
related to changes in management (A: p=0.121; B: p=0.696; p: p=0.090 L1-3: p=0.222; 
L4: p=0.812). On the contrary, reasons for CTE and MRE and context were 
significantly related to the outcome (table 5).  
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Regarding the endoscopy performed at the time of CTE and MRE, since no 
statistically significant association with the outcome (p = 0.089) was found, its 
correction was not necessary for the evaluation of the role of cross-sectional imaging in 
the patients’ outcome. 
 
Association between specific CTE or MRE findings and change in management 
Tables 6 and 7 show the results regarding the association between specific 
radiological signs and possible outcomes. When comparing the specific CTE and MRE 
features with the outcomes (change in management plan and no change in management 
plan), of the 70 patients with normal CTE or MRE, 18 (30%) had a change in outcome; 
of which 20% the outcome consisted of escalating therapy and 6% in de-escalating 
therapy. In our study, patients with wall thickening (74%), mucosal enhancement 
(65%), mural stratification (29%) and stenosis (28%) detected by the CTE or MRE were 
more likely to have a change in management plans. However, the only statistically 
significant association found was the presence of mural stratification (p = 0.019). 
Escalating therapy was more commonly associated with bowel wall thickening (74%), 
mucosal enhancement (69%), mural stratification (29%) and stenosis (32%), whereas 
bowel wall thickening (74%), mucosal enhancement (56%), mural stratification (28%) 
and comb sign (28%) were more often related to de-escalating therapy. 
Among the changes in management plan, the presence of 2 or 3 signs is the most 
common combination (24% and 22%, respectively). However, 5 or 6 signs are more 
frequently associated with changes in the therapeutic scheme. Table 8 shows the 
relationship between the number of radiological signs and the outcome. 
 
Association between specific CTE or MRE findings and specific outcomes 
For patients whose outcome consisted of the introduction of an 
immunomodulator (table 9), the most common CTE and MRE findings were: bowel 
wall thickening (82%), mural hyperenhancement (79%), mural stratification (38%), 
presence of fistulae (27%) and presence of stenosis (27%). Mural hyperehancement and 
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mural stratification on CTE and MRE were strongly related to this specific outcome (p 
values of 0.016 and 0.019, respectively).  
The presence of ulcers, abscesses, and stenosis most commonly led to the 
introduction of an anti-TNFα agent (table 10). The CTE and MRE findings reported in 
the only case where the outcome was the increase of the dose of the immunomodulator 
(table 11) were mural hyperenhancement and the presence of ulcerative disease. All 
radiological signs of active disease showed a higher frequency for increasing the dose of 
anti-TNFα agent (table 12) compared to not changing the management plan, except in 
the presence of an abscess. In the group of patients who changed to a different 
immunomodulator (table 13), the CTE and MRE finding that was most frequently 
related with this outcome was the presence of stricturing disease. It is noteworthy that 
none of these associations were found to be statistically significant. 
In the only case whose outcome consisted of shortening the interval between the 
administration of an anti-TNFα agent (table 14), only the ulcerative and structuring 
disease were found. However, only the association of ulcerative disease with this 
outcome was found to be statistically relevant (p= 0.023). 
 
Discussion 
CTE and MRE have an established role in evaluating patients with CD, by 
providing additional information to clinical and endoscopic assessment, which is crucial 
for proper patient management.
17
   
Ileocolonoscopy is the gold-standard for assessment of ileocolonic CD, although 
the examination has certain limitations
12
, such as the inability to determine disease 
severity in the small bowel and to evaluate extraluminal complications. CTE and MRE 
should represent an important step in the diagnostic, therapeutic and prognostic 
management of the disease in order to their ability to evaluate not only the intestinal 
mucosa, but also the entire bowel wall, and to detect extra luminal complications.
 18,19
 
CTE and MRE have a high and comparable sensitivity (85.8% vs. 87.9%) and 
specificity (83.6% vs. 81.2%) for active small bowel inflammation and can objectively 
assess response to medical therapy.
 11,13
 Our study aimed to determine how specific 
CTE and MRE findings influenced gastroenterologists’ therapeutic decisions for 
11 
 
patients with CD. Thereunto, we evaluated 349 patients with a previously established 
diagnosis of CD. In contrast to other studies, we simultaneously evaluated patients who 
had undergone a CTE (85% of the sample) and a MRE (15%). 
The present study demonstrated that CTE and MRE alter the management plans 
in 40% of patients with established CD, which is in line with a previous report by a 
related study from Bruining et al
7
. His team verified that CTE changes the management 
plans in more than 50% of patients with established or suspected CD. In another study, 
Bruinning et al
20
 also demonstrated that the CTE finding of penetrating disease 
significantly alter management plans, including the start of antibiotic therapy, surgical 
referral, and the use of immunosuppressive or biologic agents. Booya et al
21
 described 
the detection of occult penetrating disease by CTE, leading to a change in management 
in 61% of patients with CD. On the other hand, Figueiredo et al
22
 found that MRE 
played a decisive role in clinical decision making, leading to a change in management 
plans in more than half of patients. This study also confirms a previous retrospective 
report by Mendonza et al
23
, in which MRE findings were useful for escalating medical 
treatment for almost 50% of patients in whom it was performed for the purpose of 
monitoring medical treatment. 
When compared to previously studies, the patients who underwent CTE or MRE 
in our study were more likely to have the age at the time of diagnosis <40 years old 
(84%), small bowel disease (89%) and more complex disease behavior as shown by the 
high proportion of patients with stricturing and penetrating disease (53%). Age at the 
time of diagnosis <40 years old, small bowel disease and stricturing and penetrating 
disease (bowel damage) are some of the prognostic factors for severe disease and 
development of complications.
 24
 In a previous retrospective study by Mendonza et al
23
 
70% of the cases were under 40 years old at the time of diagnosis, 65% had small bowel 
disease and 49% had stricturing or penetrating disease. However, in both studies, 24% 
of the cases had undergone previous surgery. In another study, Messaris et al
25
 studied a 
sample of 120 patients diagnosed or suspected of CD, of which 83% were diagnosed at 
the age of 40, 83% had small bowel disease, and 23% were found to have stricturing or 
penetrating diseases. Therefore, we can assume that our sample of patients with CD was 
more likely to have a more complex phenotype of the disease compared with other 
studies. Consequently, it is not surprising that the most common outcomes in the present 
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study include the addition of potent anti-inflammatory medications: immunomodulators 
(10%), anti-TNFα agents (8%) and corticosteroids (6%).  
When comparing the reason and the context of the CTE and MRE with the 
outcome (table 5), we found that patients who underwent CTE or MRE for CD follow-
up and within the context of a consultation were more likely to have no change in their 
management plan (65% and 63% vs. 35% and 37%, respectively). On the contrary, for 
patients who underwent CTE or MRE due to acute CD complication and for those who 
were hospitalized, a greater proportion presented changes in the outcome (56% and 54% 
vs. 44% and 46%, respectively), particularly with escalating therapy (42% of 56%). 
These results are most likely related to the severity and acute presentation of the 
disease. 
In the present study, 17% of the 349 CTE and MRE performed were considered 
normal, and, of those, 30% had a change in outcome. The remaining 83% of the patients 
had an abnormal CTE or MRE, of which 42% had a change in their management plan. 
However, unlike the study of Rajabi et al
5
 we were not able to find a statistically 
significant association between these two variables. In their study, they found that 
having an abnormal MRE was strongly associated with a change in management 
(p=0.008).   
The most frequent CTE/MRE findings were bowel wall thickening (71%) and 
mural hyperenhancement (60%). Bowel wall thickening (bowel wall greater than 3mm 
in thickness) is often asymmetric, usually more prominent along the mesenteric border. 
Mural hyperenhancement is the most relevant finding for active disease and corresponds 
to a segmental attenuation greater than the adjacent normal small bowel loops.
26,27
 This 
CTE/MRE findings were the most commonly signs associated with change in 
management (74% of the patients with bowel wall thickening and 65% with mural 
hyperenhancement). This data is similar to a retrospective study by Rajabi et al
5
, which 
demonstrated that patients who had a change in management were more likely to have 
findings of circumferential wall thickening on MRE, as well as reactive lymph nodes. 
Another abnormality associated with active disease is comb sign (engorgement of vasa 
recta), but it has limited sensitivity and specificity for determining the presence of 
active inflammation.
28
 In the present study, comb sign was present in 22% of the 
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patients and was more commonly associated with no change in management than with a 
change in outcome (55% and 46%, respectively, with p>0.05). 
In addition to the signs of active disease, grading the severity of lesions is of 
vital importance in clinical practice since it has therapeutic and prognostic implications. 
The CTE and MRE findings associated to severe disease are the presence of edema, 
ulcerations, structuring disease and penetrating disease.
28
 Mural stratification (figures 1 
and 2) was present in 22% of the patients in the present study. This radiologic signal 
refers to a laminated appearance of thickened wall, due to mural edema.
 26
 It has been 
suggested that mural hyperenhancement, without stratification, may be more common 
in the early stages of CD, whereas mural stratification may indicate more advanced 
disease.
 3
 Furthermore, mural edema is predominantly identified in segments with 
severe inflammatory lesions.
 28
 In our study, we have found that the only CTE/MRE 
finding that correlates significantly with change in management was mural stratification 
(p<0.05), which may be related to more advanced and severe disease in those patients. 
Furthermore, mural hyperenhancement and mural stratification were significantly 
associated with the introduction of immunomodulator (p=0.016 and p=0.019, 
respectively), corresponding to 79% and 38% of CTE/MRE findings associated with 
this outcome. Ulcerations are more commonly found on the mesenteric border of the 
bowel and their appearance may vary from subtle lesions (fissuring ulcerations) to deep 
lesions in a thickened hyperenhanced wall.
 28
 Presence of ulcerating disease was shown 
to lead more commonly to an escalation in therapy (50%) than to no change in the 
management plan (38%) or de-escalating therapy (13%).  
Fibrostenosing and penetrating disease are the main complications of CD. 
Abscess, fistulae and stenosis are clearly signs of bowel damage, and the proportion of 
patients developing these complications increases over the years after a diagnosis of 
CD.
 19
 Cross-sectional imaging, specifically CTE and MRE, are essential in the 
evaluation of these complications, since, unlike endoscopic methods, they are able to 
delineate fistulous pathways, detect abscesses, and identify, locate and evaluate the 
extent of stricturing processes.
28
 In our study, the presence of fistulae, abcesses and 
stenosis were more commonly associated with the introduction of an immunomodulator 
and with the introduction of an anti-TNFα agent when compared to other outcomes. 
However, only stenosis were marginally associated with a change in management 
(p=0.067), but none of these findings were found to be strongly correlated with any 
14 
 
outcome (p>0.05). In contrast, Rajabi et al
5
 found that the presence of an abcess or 
phlegmon on MRE was significantly associated (p= 0.03) with a change in 
management, but they were not able to find a significant association between the 
presence of fistulae and a change in management.  
The increased accessibility of cross-sectional imaging methods in recent years 
has led to an increase in the number of CT scans prescribed. Factors like young age at 
the time of diagnosis, the recurrent nature of the disease and the introduction of 
biological therapies, are related to the increased use of CTE and, consequently, to a 
higher cumulative radiation exposure. Thus, since MRE is a radiation-free method, it is 
the preferred cross-sectional imaging technique for monitoring patients with CD.
29
 
Scoring of disease activity is important for objective assessment, and several indices 
have been proposed. Rimola et al
29
 proposed and validated the most widely used MRE 
score - MaRIA score - that includes wall thickening, mucosal hyperenhancement and 
presence of edema and ulcers. This index has been successfully validated using a cohort 
of 49 patients and ileocolonoscopy as the reference standard.
14
 It was demonstrated that 
the MaRIA score has a high accuracy for detection of active disease, severe disease, 
while also providing an objective, quantitative and reproducible measure of disease 
activity.
14
 Notwithstanding, this score does not appear to guide the management of CD 
patients and does not take into account important parameters concerning CD severity, 
such as the presence of stricturing disease or penetrating disease. Therefore, the 
development of severity scores that take these signs into account is relevant, providing 
important additional information about the real activity of the disease and allowing 
clinicians to make more informed decisions about the best therapeutic option for each 
case. In our study, several CTE and MRE findings were shown to be strongly related to 
specific outcomes: mural hyperenhancement and mural stratification with 
the introduction of an immunomodulator; and ulcerative disease with shortening of the 
interval between the administration of an anti-TNFα agent. These results lead us to 
believe that specific CTE and MRE findings, and perhaps new disease scoring systems, 
may help to stratify treatment options. However, further studies are required to validate 
this. 
Our study highlights the importance of CTE and MRE features on the outcome 
of patients with CD, providing additional data about parameters that are most likely to 
influence clinicians’ management plans of these patients. However, several limitations 
15 
 
of this study are evident. Given its retrospective nature, the existence of evaluation and 
detection biases is a possibility. Many patients had incomplete clinical data, which may 
have also influenced the results. Moreover, the elaboration of CTE and MRE reports by 
different radiologists and their evaluation and interpretation by non-radiologists may 
also be a factor of subjectivity and bias in the study.  To prove the value of CTE and 
MRE in clinical assessment of CD, prospective studies are needed to determine whether 
the information obtained from CTE/MRE actually changes clinical decision making and 
clinical outcomes, and how can these imaging techniques contribute as a guide to the 
best therapeutic decisions. 
In conclusion, the goal of our study was to retrospectively assess the impact of 
CTE and MRE on the therapeutic decision making for patients with CD. We found that 
CTE and MRE in CD patients presented important information, regarding disease 
activity and behavior, which played a decisive role in clinical decision making, leading 
to a therapeutic change in 40% of patients. Furthermore, mural stratification, a sign of 
CD’s severity, showed to be strongly related with the outcome. These data provide 
additional support favoring the routine use of these imaging techniques in the 
monitoring and therapeutic management for patients with CD. 
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Tables 
Table 1. Baseline characteristics of patients with Crohn's Disease who were included in the study (CTE – 
Computed Tomography Enterography; MRE – Magnetic Resonance Enterography) 
 n (%) 
Demographics  
Female 161 (46) 
Male 188 (54) 
Median age (range) 34 (11-76) 
Age < 18 years old 33(10) 
Age at diagnosis 
 
A1 69 (20) 
A2 218 (64) 
A3 54 (16) 
Behaviour 
 
B1 162 (48) 
B2 77 (23) 
B3 102 (30) 
P 74 (22) 
Location 
 
L1 158 (45) 
L2 38 (11) 
L3 152 (44) 
L4 63 (18) 
CTE’s and MRE’s Reason 
 
Follow-up 271 (78) 
Acute complication 78 (22) 
CTE’s and MRE’s context 
 
Appointment 291 (83) 
Internment 58 (17) 
History of Hospitalization 235 (67) 
History of Surgery 83 (24) 
 
  
21 
 
Table 2. Computed Tomography Enterography and Magnetic Resonance Enterography findings 
 n (%) 
Bowel wall thickening 249 (71) 
Mucosal enhancement 210 (60) 
Mural stratification 78 (22) 
Comb sign 77 (22) 
Ulcer 8 (2) 
Fistulae 66 (19) 
Abscess 11 (3) 
Stenosis 83 (24) 
None 60 (17) 
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Table 3. Categorization of the outcomes in study 
No change in 
management 
Escalating therapy De-escalating therapy 
 1. Introduction of immunomodulator  1. Suspension of immunomodulator  
 2. Introduction of anti-TNF agent  2. Suspension of anti-TNF agent  
 
3. Dose increase of immunomodulator  
3. Dose decrease of 
immunomodulator  
 4. Dose increase of anti-TNF agent  4. Dose decrease of anti-TNF agent  
 
5. Shortening the interval between 
administrations of anti-TNF agent  
5. Extending  the interval between 
administrations of anti-TNF 
agent  
 6. Change to a different 
immunomodulator  
6. Suspension of corticosteroids 
 7. Change to a different anti-TNF agent  7. Decreased corticosteroid dose 
 8. Introduction of corticosteroid  8. Suspension of aminosalicylates  
 9. Dose increase of corticosteroid 9. Suspension of polymeric diet 
 10. Introduction of aminosalicylates   
 11. Introduction of polymeric diet   
 12. Surgery  
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Table 4. Frequency of the outcomes 
Outcome n (%) 
No change in management 210 (60) 
Escalating therapy  
Introduction of immunomodulator  34 (10) 
Introduction of anti-TNFα agent  28 (8) 
Dose increase of immunomodulator  1 (0) 
Dose increase of anti-TNFα agent  13 (4) 
Shortening the interval between administrations of 
anti-TNFα agent  
1 (0) 
Change to a different immunomodulator  3 (1) 
Change to a different anti-TNFα agent  0 (0) 
Introduction of corticosteroid  20 (6) 
Dose increase of corticosteroid 1 (0) 
Introduction of aminosalicylates  7 (2) 
Introduction of polymeric diet  0 (0) 
Surgery 0 (0) 
De-escalating therapy  
Suspension of immunomodulator  11 (3) 
Suspension of anti-TNFα agent  5 (1) 
Dose decrease of immunomodulator  4 (1) 
Dose decrease of anti-TNFα agent  0 (0) 
Extending  the interval between administrations of 
anti-TNFα agent  
0 (0) 
Corticosteroids suspension 1 (0) 
Decreased corticosteroid dose 18 (5) 
Suspension of aminosalicylates  3 (1) 
Suspension of polymeric diet 9 (3) 
Suspension of immunomodulator  4 (1) 
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Table 5. Reason and context in which the Computed Tomography Enterography and Magnetic 
Resonance Enterography were carried out and their repercussion on the clinical management for the CD 
patients in study (0 – No change in management plan; 1 – Escalating therapy; 2 – De-escalating therapy; 
R/C– Reason/Context; Out – Outcome) 
 
Outcome 
p  
0 1 2 
 
n=210 n=96 n=43 
 
n %R/C %Out n % R/C %Out n % R/C %Out 
Follow-up 175 65 83 63 23 66 32 12 74 0.002 
Acute complication 35 45 17 32 42 33 11 14 26 0.004 
Appointment 184 63 88 73 25 76 35 12 81 0.036 
Internement 26 46 12 23 40 24 8 14 18 0.036 
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Table 6. The impact of specific Computed Tomography Enterography and Magnetic Resonance 
Enterography findings on patients’ outcome (0 – No change in management plan; 1 – Change in 
management plan; RS – Radiological Signs; Out - Outcome) 
 
Outcome 
p  
0 1 
 
n=210 n=139 
 
n %RS %Out n %RS %Out 
None 42 70 20 18 30 13 0,087 
Bowel wall thickening 146 59 70 103 41 74 0,355 
Mucosal enhancement 120 57 57 90 43 65 0,155 
Mural estratification 38 49 18 40 51 29 0,019 
Comb sign 42 55 20 35 46 25 0,253 
Ulcer 3 38 1 5 63 4 0,274 
Fistulae 35 53 17 31 47 22 0,188 
Abscess 6 55 3 5 46 4 0,759 
Stenosis 44 53 21 39 47 28 0,127 
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Table 7. The impact of specific Computed Tomography Enterography and Magnetic Resonance 
Enterography findings on patients outcome (0 – No change in management plan; 1 – Escalating therapy; 2 
– De-escalating therapy; RS – Radiological Signs; Out – Outcome) 
 
Outcome 
p  
0 1 2 
 
n=210 n=96 n=43 
 
n %RS %Out n %RS %Out n %RS %Out 
None 42 70 20 12 20 13 6 10 14 0,227 
Bowel wall 
thickening 
146 59 70 71 29 74 32 13 74 0,650 
Mucosal 
enhancement 
120 57 57 66 31 69 24 11 56 0,129 
Mural 
estratification 
38 49 18 28 36 29 12 15 28 0,063 
Comb sign 42 55 20 23 30 24 12 16 28 0,455 
Ulcer 3 38 1 4 50 4 1 13 2 0,185 
Fistulae 35 53 17 20 30 21 11 17 26 0,338 
Abscess 6 55 3 3 27 3 2 18 5 0,699 
Stenosis 44 53 21 31 37 32 8 10 19 0,067 
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Table 8. Number of Computed Tomography Enterography and Magnetic Resonance Enterography 
findings and their repercussion on the outcome of CD patients (0 – No change in management plan; 1 – 
Change in management plan; RS – Radiological Signs; Out - Outcome) 
 
Outcome 
p  
0 1 
 
n=210 n=139 
CTE/MRE findings n %RS %Out n %RS %Out 
0 42 71 20 17 29 12 
0,115 
1 29 59 14 20 41 14 
2 61 65 29 33 35 24 
3 44 59 21 31 41 22 
4 22 52 11 20 48 14 
5 10 42 5 14 58 10 
6 2 33 1 4 67 3 
 
  
28 
 
Table 9. Impact of specific Computed Tomography Enterography and Magnetic Resonance Enterography 
findings on specific outcomes – Introduction of immunomodulator (0 – No change in management plan; 1 
– Change in management plan; RS – Radiological Signs; Out - Outcome) 
 
Introduction of immunomodulator 
p  
0 1 
 
n=315 n=34 
 
n %RS %Out n %RS %Out 
None 59 98 19 1 2 3 0.020 
Bowel wall thickening 221 89 70 28 11 82 0.135 
Mucosal enhancement 183 87 58 27 13 79 0.016 
Mural estratification 65 83 21 13 17 38 0.019 
Comb sign 71 92 23 6 8 18 0.513 
Ulcer 7 88 2 1 13 3 0.563 
Fistulae 57 86 18 9 14 27 0.236 
Abscess 9 82 3 2 18 6 0.291 
Stenosis 74 89 24 9 11 27 0.698 
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Table 10. Impact of specific Computed Tomography Enterography and Magnetic Resonance 
Enterography findings on specific outcomes – Introduction of anti-TNFα agent  (0 – No change in 
management plan; 1 – Change in management plan; RS – Radiological Signs; Out - Outcome) 
 
Introduction of anti-TNFα agent 
p  
0 1 
 
n=321 n=28 
 
n %RS %Out n %RS %Out 
None 52 87 16 8 13 29 0.115 
Bowel wall thickening 233 94 72 16 6 57 0.083 
Mucosal enhancement 194 92 60 16 8 57 0.733 
Mural estratification 74 95 23 4 5 14 0.286 
Comb sign 74 96 23 3 4 11 0.131 
Ulcer 7 88 2 1 13 4 0.491 
Fistulae 61 92 19 5 8 18 0.882 
Abscess 10 91 3 1 9 4 0.605 
Stenosis 76 92 24 7 8 25 0.875 
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Table 11. Impact of specific Computed Tomography Enterography and Magnetic Resonance 
Enterography findings on specific outcomes – Dose increase of immunomodulator (0 – No change in 
management plan; 1 – Change in management plan; RS – Radiological Signs; Out - Outcome) 
 
Dose increase of immunomodulator 
p  
0 1 
 
n=348 n=1 
 
n %RS %Out n %RS %Out 
None 60 100 17 0 0 0 1.000 
Bowel wall thickening 249 100 72 0 0 0 0.287 
Mucosal enhancement 209 100 60 1 0 100 1.000 
Mural estratification 78 100 22 0 0 0 1.000 
Comb sign 76 99 22 0 0 0 0.221 
Ulcer 8 100 2 1 2 100 1.000 
Fistulae 65 99 19 0 0 0 0.189 
Abscess 11 100 3 0 0 0 1.000 
Stenosis 82 99 24 1 1 100 0.238 
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Table 12.  Impact of specific Computed Tomography Enterography and Magnetic Resonance 
Enterography findings on specific outcomes – Shortening the interval between administrations of anti-
TNFα agent (0 – No change in management plan; 1 – Change in management plan; RS – Radiological 
Signs; Out - Outcome) 
 
Shortening the interval between administrations 
of anti-TNFα agent 
p  
0 1 
 
n=348 n=1 
 
n %RS %Out n %RS %Out 
None 60 100 17 0 0 0 1.000 
Bowel wall thickening 249 100 72 0 0 0 0.287 
Mucosal enhancement 210 100 60 0 0 0 0.398 
Mural estratification 78 100 22 0 0 0 1.000 
Comb sign 77 100 22 0 0 0 1.000 
Ulcer 7 84 2 1 13 100 0.023 
Fistulae 66 100 19 0 0 0 1.000 
Abscess 11 100 3 0 0 0 1.000 
Stenosis 82 99 24 1 1 100 0.238 
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Table 13. Impact of specific Computed Tomography Enterography and Magnetic Resonance 
Enterography findings on specific outcomes – Dose increase of anti-TNFα agent (0 – No change in 
management plan; 1 – Change in management plan; RS – Radiological Signs; Out - Outcome) 
 
Dose increase of anti-TNF agent 
p  
0 1 
 
n=336 n=13 
 
n %RS %Out n %RS %Out 
None 59 98 18 1 2 8 0.706 
Bowel wall thickening 239 96 71 10 4 77 0.765 
Mucosal enhancement 200 95 60 10 5 77 0.209 
Mural estratification 75 96 22 3 4 23 1.000 
Comb sign 72 94 21 5 7 39 0.171 
Ulcer 7 88 2 1 13 8 0.264 
Fistulae 62 94 19 4 6 31 0.279 
Abscess 11 100 3 0 0 0 1.000 
Stenosis 79 95 24 4 5 31 0.517 
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Table 14.  Impact of specific Computed Tomography Enterography and Magnetic Resonance 
Enterography findings on specific outcomes – Change to a different immunomodulator (0 – No change in 
management plan; 1 – Change in management plan; RS – Radiological Signs; Out - Outcome) 
 
Change to a different immunomodulator 
p  
0 1 
 
n=346 n=3 
 
n %RS %Out n %RS %Out 
None 60 100 17 0 0 0 1.000 
Bowel wall thickening 247 99 71 2 1 67 1.000 
Mucosal enhancement 209 100 60 1 0 33 0.566 
Mural estratification 77 99 22 1 1 33 0.533 
Comb sign 77 100 22 0 0 0 1.000 
Ulcer 8 100 2 0 0 0 1.000 
Fistulae 66 100 19 0 0 0 1.000 
Abscess 11 100 3 0 0 0 1.000 
Stenosis 82 99 24 2 1 33 0.558 
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Figure Legends 
Figure 1. Stratified appearance in Crohn’s Disease. Axial and coronal contrast-enhanced Computed 
Tomography Enterography scan of the abdomen shows concentric wall thickening of small bowel loop 
with a stratified appearance indicating active disease. Also note a fistula connecting the bowel loops, a 
common finding in penetrating subtype of Crohn’s Disease. 
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Figure 2. Axial contrast enhanced and T2 haste images of Magnetic Resonance Enterography show 
bowel wall thickening (double arrows), luminal fluid (*) and bowel wall stratification with mucosal and 
serosal avidly enhancing when compared to submucosa, in a patient with Crohn´s Disease.  
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consecutively in the manuscript, and number them in the order in which they are discussed. 
Figure Legends Legends must be submitted for all figures. They should be brief and 
specific, and they should appear after the tables. Use scale markers in the image for electron 
micrographs, and indicate the type of stain used. 
Color Figures At no cost to the author, the journal accepts for publication color figures that 
will enhance the article. Figures are also published online in color at no cost. 
Steps for Submitting Artwork  
1. Please reference "5 Steps to Creating Digital Artwork (pdf)" available 
at http://edmgr.ovid.com/lww-final/accounts/5StepsforArt.pdf, specifically steps 2 and 3, 
when creating figures for submission.  
2. Create, Scan and Save according to the "5 Steps to Creating Digital Artwork (pdf)".  
3. Compare your final figure to the Target Digital-Imaging Results listed below.  
4. Upload each figure to the journal's online submission system in conjunction with your 
manuscript text and tables. 
Digital Artwork Guideline Checklist 
Here are the basics to have in place before submitting your digital art to Inflammatory Bowel 
Diseases. Artwork saved as TIFF and EPS files. Do not save TIFFs as compressed files. 
PowerPoint files are also acceptable. 
 Artwork created as the actual size (or slightly larger) it will appear in the journal. (To 
get an idea of the size images should be when they print, study a copy of the journal 
to which you wish to submit. Measure the artwork typically shown and scale your 
image to match.) 
 Crop out any white or black space surrounding the image. 
 Text and fonts in any figure are one of the acceptable fonts: Helvetica, Times 
Roman, Symbol, Mathematical PI, and European PI. 
 Color images are created/scanned and saved and submitted as CMYK only. Do not 
submit any figures in RGB mode because RGB is the color mode used for 
screens/monitors and CMYK is the color mode used for print. 
 Line art saved at a resolution of at least 1200 dpi. 
 Images saved at a resolution of at least 300 dpi. 
 Each figure saved as a separate file and saved separately from the accompanying 
text file. 
 For multi-panel or composite figures only: Any figure with multiple parts should be 
sent as one file with each part labeled the way it is to appear in print. 
Remember: 
 Artwork generated from office suite programs such as CorelDRAW, MS Word, Excel, 
and artwork downloaded from the Internet (JPEG or GIF files) cannot be used 
because the quality is poor when printed. 
 Cite figures consecutively in your manuscript. 
 Number figures in the figure legend in the order in which they are discussed. 
 Upload figures consecutively to the journal's online submission system and number 
figures consecutively in the Description box during upload. 
Tables Create tables using the table creating and editing feature of your word processing 
software (e.g., Word). Do not use Excel or comparable spreadsheet programs. Do not submit 
tables as image files or images placed in Word documents, tables must be provided as 
editable text (Word files are preferred). Submit all tables as separate files. Cite tables 
consecutively in the text, and number them in that order. Key each on a separate sheet, and 
include the table title, appropriate column heads, and explanatory legends (including 
definitions of any abbreviations used). Do not imbed tables within the body of the 
manuscript. They should be self-explanatory and should supplement, rather than duplicate, 
the material in the text. 
Supplemental Digital Content (SDC) Authors may submit supplementary materials via 
the journal's online submission system that enhance their article's text to be considered for 
online posting. SDC may include standard media such as text documents, graphs, audio, 
video, etc. On the Attach Files page of the submission process, please select Supplemental 
Audio, Video, or Data for your uploaded file as the Submission Item. If an article with SDC is 
accepted, our production staff will create a URL with the SDC file. The URL will be placed in 
the call-out within the article. SDC files are not copy-edited by LWW staff, they will be 
presented digitally as submitted. Please supply the SDC files as you would like them to 
appear in final publication (include legends in the same file as the images; make text double 
spaced or single spaced per your preference). For a list of all available file types and detailed 
instructions, please visit http://links.lww.com/A142. 
SDC Call-outs Supplemental Digital Content must be cited consecutively in the text of the 
submitted manuscript. Citations should include the type of material submitted (Audio, Figure, 
Table, etc.), be clearly labeled as "Supplemental Digital Content," include the sequential list 
number, and provide a description of the supplemental content. All descriptive text should be 
included in the call-out as it will not appear elsewhere in the article. 
Example: We performed many tests on the degrees of flexibility in the elbow (see Video, 
Supplemental Digital Content 1, which demonstrates elbow flexibility) and found our results 
inconclusive. 
List of Supplemental Digital Content A listing of Supplemental Digital Content must be 
submitted at the end of the manuscript file. Include the SDC number and file type of the 
Supplemental Digital Content. This text will be removed by our production staff and not be 
published. 
Example:  
Supplemental Digital Content 1.wmv 
SDC Files Requirements All acceptable file types are permissible up to 10 MBs. For audio 
or video files greater than 10 MBs, authors should first query the journal office for approval. 
For a list of all available file types and detailed instructions, please 
visit http://links.lww.com/A142. 
Style Follow American Medical Association Manual of Style (10th edition). Stedman's Medical 
Dictionary (27th edition) and Merriam Webster's Collegiate Dictionary (10th edition) should 
be used as standard references. Refer to drugs and therapeutic agents by their accepted 
generic or chemical names, and do not abbreviate them. Use code numbers only when a 
generic name is not yet available. In that case, supply the chemical name and a figure giving 
the chemical structure of the drug. Capitalize the trade names of drugs and place them in 
parentheses after the generic names. To comply with trademark law, include the name and 
location (city and state in USA; city and country outside USA) of the manufacturer of any 
drugs, supplies, or equipment mentioned in the manuscript. Use the metric system to 
express units of measure and degrees Celsius to express temperatures, and use SI units 
rather than conventional units. 
Basic and Clinical IBD Review Articles Guidelines Basic and clinical IBD Review articles 
should present recent advances in a relatively narrow topic that have been made in cutting 
edge research. 
The goal of the basic and clinical IBD review articles should be to present a complete 
summary of important research areas that are now improving our understanding of Crohn's 
disease and ulcerative colitis. 
The body of basic and clinical IBD Review articles should be no longer than 20 double spaced 
pages (not including references, figures, and tables). There should be no more than 6 tables 
and figures (combined). Supplemental figures and tables will be allowed online. If page limits 
need to be increased, the authors may request permission from the Editors to increase the 
length of the Review article. The number of references should be limited to 100. The Review 
article should be focused on a single specific topic. All review articles will be peer-reviewed. 
Future Directions and Methods for IBD Research Guidelines Original research articles 
and review articles on future directions and methods for IBD research should discuss 
important basic and clinical areas in which investigators should focus their efforts to provide 
a deeper understanding of IBD research areas in which rapid advances and novel concepts 
can be made. In addition, the Future Directions and Methods for IBD original research 
articles and review articles should include a discussion of areas in which improved 
methodologic tools have been identified and exactly how those methods should be 
performed. Basic science directions and methods should be presented that will expand our 
knowledge of areas that will allow novel insights to be made regarding the genetic, 
immunologic, microbial and environmental interactions that are the basis of the pathogenesis 
of Crohn's disease and ulcerative colitis. Clinical directions and methods should be presented 
that will allow investigators to make advances using cohort studies, multicenter registries, 
risk stratifications, and treatment outcomes. The goal of the Future Directions and Methods 
for clinical IBD original research articles and review articles should be to better understand 
the challenging biological variables in IBD patients and to provide optimal evidence of novel 
therapeutics that will more effectively treat, cure, and prevent Crohn's disease and ulcerative 
colitis. 
Original research articles, for the Future Directions and Methods for IBD research section, 
should be written as described in the IBD Journal Instructions for original research articles. 
Review articles, for the Future Directions and Methods for IBD research section, should be no 
longer than 35 double spaced pages (including references and figure legends). There should 
be no more than 6 tables and figures (combined). Supplemental figures and tables will be 
allowed online. If page limits need to be increased, the authors may request permission from 
the Editors to increase the length of their future directions and methods for IBD research 
review article. The number of references should be limited to 100. The future directions and 
methods for IBD research review article should be focused on a single specific topic. 
Letters to the Editor Guidelines Letters in response to articles published in the journal are 
welcome and should be submitted via IBD's online submission system. All Letters should 
start with the phrase "To the Editors," and be written as a letter. Letters must be submitted 
the end of the following calendar month (e.g. by the end of July, for letters referring to 
articles in the June print issue) and be a maximum of 400 words, with no more than one 
figure or table and no more than 5 references. All LTEs will be published online-only. 
Research letters and case-based discussions will no longer be accepted for submission 
effective November 1, 2012. 
REVISIONS 
When submitting a revision, please submit both a clean copy and marked copy of the 
manuscript. The marked copy should highlight all of the changes made the by authors after 
the original review. Authors can use the track changes feature of the Microsoft Word 
program to create a marked copy. Authors also should submit all tables and figures in 
separate files for production purposes. 
AFTER ACCEPTANCE 
Open access LWW's hybrid open access option is offered to authors whose articles have 
been accepted for publication. With this choice, articles are made freely available online 
immediately upon publication. Authors may take advantage of the open access option at the 
point of acceptance to ensure that this choice has no influence on the peer review and 
acceptance process. These articles are subject to the journal's standard peer-review process 
and will be accepted or rejected based on their own merit. 
Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual 
unrestricted online access to their published article to readers globally, immediately upon 
publication. The article processing charge for Inflammatory Bowel Diseases is $3,000. The 
article processing charge for authors funded by the Research Councils UK (RCUK) is $3,800. 
The publication fee is charged on acceptance of the article and should be paid within 30 days 
by credit card by the author, funding agency or institution. Payment must be received in full 
for the article to be published open access. 
 Authors retain copyright Authors retain their copyright for all articles they opt to 
publish open access. Authors grant LWW a license to publish the article and identify 
itself as the original publisher. 
 Creative Commons license Articles opting for open access will be freely available 
to read, download and share from the time of publication. Articles are published 
under the terms of the Creative Commons License Attribution-NonCommerical No 
Derivative 3.0 which allows readers to disseminate and reuse the article, as well as 
share and reuse of the scientific material. It does not permit commercial exploitation 
or the creation of derivative works without specific permission. To view a copy of this 
license visit: http://creativecommons.org/licenses/by-nc-nd/3.0. 
 Compliance with NIH, RCUK, Wellcome Trust and other research funding 
agency accessibility requirements A number of research funding agencies now 
require or request authors to submit the post-print (the article after peer review and 
acceptance but not the final published article) to a repository that is accessible online 
by all without charge. As a service to our authors, LWW identifies to the National 
Library of Medicine (NLM) articles that require deposit and transmits the post-print of 
an article based on research funded in whole or in part by the National Institutes of 
Health, Howard Hughes Medical Institute, or other funding agencies to PubMed 
Central. The revised Copyright Transfer Agreement provides the mechanism. LWW 
ensures that authors can fully comply with the public access requirements of major 
funding bodies worldwide. Additionally, all authors who choose the open access 
option will have their final published article deposited into PubMed Central. RCUK and 
Wellcome funded authors can choose to publish their paper as open access with the 
payment of an article process charge (gold route), or opt for their accepted 
manuscript to be deposited (green route) into PMC with an embargo. With both the 
gold and green open access options, the author will continue to sign the Copyright 
Transfer Agreement (CTA) as it provides the mechanism for LWW to ensure that the 
author is fully compliant with the requirements. After signature of the CTA, the 
author will then sign a License to Publish where they will then own the copyright. 
Those authors who wish to publish their article via the gold route will be able to 
publish under the terms of the Attribution 3.0 (CCBY) License. To view of a copy of 
this license visit: http://creativecommons.org/licenses/by/2.0/. Those authors who 
wish to publish their article via the green route will be able to publish under the 
rights of the Attribution Non-commercial 3.0 (CCBY NC) license 
(http://creativecommons.org/licenses/by-nc/2.0/). It is the responsibility of the 
author to inform the Editorial Office and/or LWW that they have RCUK funding. LWW 
will not be held responsible for retroactive deposits to PMC if the author has not 
completed the proper forms. 
FAQ for open access http://links.lww.com/LWW-ES/A48 
Page Proofs and Corrections - Corresponding authors will receive an e-mail containing a 
link to the electronic page proofs to check the copyedited and typeset article before 
publication. The pages proofs are provided as portable document format (PDF) files which 
require Adobe Reader to be viewed and edited. Complete instructions will be provided with 
the e-mail for downloading the files and for returning the corrected pages electronically to 
the publisher. It is the author's responsibility to ensure that there are no errors in the proofs. 
Changes that have been made to conform to journal style should be allowed to stand if they 
do not alter the authors' meaning. Authors may be charged for alterations to the proofs 
beyond those required to correct errors or to answer queries. Proofs must be checked 
carefully and corrections returned within 24 to 48 hours of receipt, as requested in the 
communication accompanying the page proofs. 
Reprints - The corresponding author will receive the reprint order form via e-mail while the 
article is in production. Reprint requests can be submitted any time before or after 
publication of the article. For orders submitted before the article is published, the reprints 
are normally shipped 6 to 8 weeks after publication of the issue in which the item appears. 
For any questions regarding reprints or publication fees, contact the Reprint Department by 
mail at Lippincott Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201; by 
phone at 1-800-341-2258; by fax at 410-528-4434; or by e-mail 
at: reprints@wolterskluwer.com. 
Permissions - For permission and/or rights to use content for which the copyright holder is 
LWW or the society, please go to the journal's website and after clicking on the relevant 
article, click on the "Request Permissions" link under the "Article Tools" box that appears on 
the right side of the page. Alternatively, send an e-mail to customercare@copyright.com. 
For Translation Rights & Licensing queries, contact Silvia Serra, Translations Rights, 
Licensing & Permissions Manager, Wolters Kluwer Health (Medical Research) Ltd, 250 
Waterloo Road, London SE1 8RD, UK. Phone: +44 (0) 207 981 0600. E-
mail: silvia.serra@wolterskluwer.com 
For Special Projects and Reprints (U.S./Canada), contact Alan Moore, Director of Sales, 
Lippincott Williams & Wilkins, Two Commerce Square, 2001 Market Street, Philadelphia, PA 
19103. Phone: 215-521-8638. E-mail: alan.moore@wolterskluwer.com 
For Special Projects and Reprints (non-U.S./Canada), contact Silvia Serra, Translations 
Rights, Licensing & Permissions Manager, Wolters Kluwer Health (Medical Research) Ltd, 250 
Waterloo Road, London SE1 8RD, UK. Phone: +44 (0) 207 981 0600. E-
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